Bershad S
Department of Dermatology, The Mount Sinai School of Medicine, New York, NY, USA.
Semin Cutan Med Surg. 2001 Sep;20(3):154-61. doi: 10.1053/sder.2001.27555.
Topical retinoic acid was introduced for acne treatment three decades ago. Since that time, researchers have discovered thousands of retinoids, originally defined as chemical analogs of vitamin A. After the identification of nuclear retinoid receptors in 1987, the definition of this class expanded to include molecules that bind to and activate such receptors. The receptor-selective retinoid agents, adapalene and tazarotene, were developed in the 1990s. Other innovations of the past decade include retinoid formulations and methods aimed at limiting retinoid absorption. Cutaneous irritation may be reduced without losing retinoid efficacy by inhibiting retinoid penetration into the deep epidermis and dermis. Examples include tretinoin in slow-release vehicles and the short-contact method of tazarotene gel therapy. Only trace amounts of adapalene are absorbed after topical application, perhaps explaining its relatively low irritancy. New formulations of existing agents, such as additional concentrations of tretinoin in microsphere gel and cream formulations of tazarotene, are now under investigation for acne. Current research focused on receptor selectivity holds the promise of yielding new retinoid molecules with improved benefits and safety.
局部用维甲酸三十年前就被用于治疗痤疮。从那时起,研究人员已经发现了数千种类视黄醇,最初将其定义为维生素A的化学类似物。1987年核类视黄醇受体被鉴定出来后,这类物质的定义扩大到包括能与这类受体结合并激活它们的分子。受体选择性类视黄醇药物阿达帕林和他扎罗汀是在20世纪90年代研发出来的。过去十年的其他创新包括旨在限制类视黄醇吸收的制剂和方法。通过抑制类视黄醇渗透到深层表皮和真皮,可以在不降低类视黄醇疗效的情况下减少皮肤刺激。例子包括缓释载体中的维甲酸以及他扎罗汀凝胶疗法的短接触法。局部应用后只有痕量的阿达帕林被吸收,这可能解释了其相对较低的刺激性。现有药物的新制剂,如微球凝胶中更高浓度的维甲酸以及他扎罗汀的乳膏制剂,目前正在进行痤疮治疗研究。目前聚焦于受体选择性的研究有望产生具有更好疗效和安全性的新类视黄醇分子。